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We appreciate the attempts by Lowrie and others to
explain the suspected gender effect as simply reflecting
the difference in body size. In the analysis of our find-
ings we explored functions of body size that might dimin-
ish or erase the difference between the genders in their
response to the dialysis dose, expressed either as Kt or
Kt/V. As detailed in our paper [1], the dependence of the
dose effect on gender was not explained by differences
in body size expressed as several different parameters,
including weight, height, body surface area, water vol-
ume, and body mass index (Table 6). The dose effect was
not significantly associated with any of these size parame-
ters. In fact, the nonsignificant weak trends that were de-
tected were further diminished by correction for gender
(Table 5). Furthermore, the suggested increased mortal-
ity of males treated at the higher dose could not be ex-
plained by any consideration of body size.
A non-0 intercept for a linear relationship between
body size and required solute clearance is a clear math-
ematic concept that is difficult to understand physio-
logically. It implies an enormous amount of dialysis (or
kidney function) for very small people, and a near infinite
amount for even smaller biological organisms. Probably
the relationship is nonlinear but with a 0 intercept (e.g., a
power function of body mass). This is consistent with the
universal scaling law that relates physiologic functions to
the 3/4 power of body mass and to the current practice
of correcting the creatinine clearance or GFR for body
surface area (2/3 power of body mass) [2, 3, 4].
The effect of body size as an independent mortality risk
factor in hemodialyzed patients reported by Lowrie et al
[5] is now commonly accepted, and was also observed in
the HEMO Study (Table 4). However, the marked rota-
tion of the line depicting dose versus size in the graph
provided by Lowrie et al suggests that the relationship of
size with outcome can be altered by changing the dose.
Post-hoc analyses of our data [1] do not support such a
dependence of the effect of dose on the risk associated
with body size in a range of eKt/V from 1.16 to 1.53, but
do indicate that women were more responsive to the dose
effect than men. The risk associated with female gender,
in contrast to small body size, can be viewed as favorable
because females appeared to respond to the higher dose,
whereas both small patients and males did not.
Finally, we must reiterate two important limitations
that we noted in our paper. First, the finding of a dif-
ferent dose effect in men and women must be viewed as
a suggestion only because the level of significance was
not high in the context of multiple subgroup analyses.
Second, because the power of the study to detect effects
in subgroups is limited, it cannot rule out the possibility
of an undetected dependence of the dose effect on body
size.
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Prevention of acute
renal failure with
N-acetylcysteine—Enough
is enough?
To the Editor: As clinicians in daily practice we would
like to comment on the enormous amount of publica-
tions published in the last three years on the preven-
tion of radiocontrast-induced nephropathy (RCIN) by
N-acetylcysteine (NAC). Just recently, the last of four
meta-analyses was completed [1–4].
The dilemma a clinician faces is the enormous amount
of data in this field, and deciding if the information is
clinically valid or not. Traditionally, meta-analyses have
been the key tool in estimating a treatment benefit of
contradictory randomized controlled trial (RCT) results.
However, even at this evidence level results are inconclu-
sive. How is the clinician going to solve this problem?
From a practical point of view, it seems to be more
sensible to use the drug. A physician who is trying to
prevent RCIN in his patient is likely to administer a drug
if there is any evidence for a beneficial effect, especially
given the low adverse event profile for many years and
low cost of the drug.
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However, we doubt that further studies will change
the current confusing situation. Is it sensible to increase
research efforts in this field any further just to exclude a
possible nil effect of NAC in RCIN? Given the amount
of data generated on this topic in recent years we believe
that it is unlikely that better protection against RCIN will
be achieved by additional trials as argued by Pannu et al
[4]. We therefore suggest that science should move on to
search for even better solutions.
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Reply from the Authors
We thank Drs. Koller and Rosenkranz for their inter-
est in our meta-analysis. They suggest that further study
of NAC for the prevention of contrast nephropathy may
be unjustified, given the negligible cost and side effect
profile of this agent. Further, they allude to the difficul-
ties faced by clinicians in deciding how best to prevent
contrast nephropathy in their patients. We struggled with
these issues during preparation of our manuscript, and
did not mean to imply that clinicians should not use NAC.
Rather, as we stated in our article, we believe that data
are insufficient to recommend that NAC become the stan-
dard of care for patients receiving radiocontrast.
This distinction is important because although the costs
associated with NAC administration may be negligible,
the potential consequences of recommending an ineffec-
tive therapy as the standard of care are not—from the
perspective of both clinicians and scientists.
For clinicians, NAC use may provide a false sense of
security—hydration may be ignored, other nephrotoxic
medications may not be discontinued as they should be, or
unnecessary contrast studies might be performed because
of the perception that NAC reduces the risk of contrast
nephropathy.
For scientists, such a recommendation may stifle fur-
ther research to find more effective prophylaxis. In addi-
tion, prematurely adopting NAC as the standard of care
would jeopardize the feasibility of placebo controlled tri-
als in the future.
We fully agree that clinicians should consider the use
of NAC (together with other interventions that reduce
the risk of contrast nephropathy) in patients who must
receive radiocontrast. However, like Drs. Koller and
Rosenkranz, we believe that further work is required to
define the optimal strategy for prevention of this serious
complication—with or without the use of NAC.
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